nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfuzosin—CYP3A4—Bexarotene—hematologic cancer	0.0397	0.0829	CbGbCtD
Alfuzosin—CYP3A4—Lomustine—hematologic cancer	0.0369	0.0771	CbGbCtD
Alfuzosin—CYP3A4—Busulfan—hematologic cancer	0.0369	0.0771	CbGbCtD
Alfuzosin—CYP3A4—Thiotepa—hematologic cancer	0.0329	0.0687	CbGbCtD
Alfuzosin—CYP3A4—Methoxsalen—hematologic cancer	0.0256	0.0534	CbGbCtD
Alfuzosin—CYP3A4—Bortezomib—hematologic cancer	0.0243	0.0508	CbGbCtD
Alfuzosin—CYP3A4—Daunorubicin—hematologic cancer	0.0233	0.0486	CbGbCtD
Alfuzosin—CYP3A4—Cytarabine—hematologic cancer	0.0205	0.0429	CbGbCtD
Alfuzosin—CYP3A4—Teniposide—hematologic cancer	0.0202	0.0422	CbGbCtD
Alfuzosin—CYP3A4—Ifosfamide—hematologic cancer	0.0186	0.039	CbGbCtD
Alfuzosin—CYP3A4—Imatinib—hematologic cancer	0.0178	0.0372	CbGbCtD
Alfuzosin—CYP3A4—Ruxolitinib—hematologic cancer	0.0168	0.0351	CbGbCtD
Alfuzosin—CYP3A4—Nilotinib—hematologic cancer	0.0162	0.0338	CbGbCtD
Alfuzosin—CYP3A4—Vinorelbine—hematologic cancer	0.0161	0.0335	CbGbCtD
Alfuzosin—CYP3A4—Triamcinolone—hematologic cancer	0.0147	0.0307	CbGbCtD
Alfuzosin—CYP3A4—Dasatinib—hematologic cancer	0.0143	0.0299	CbGbCtD
Alfuzosin—CYP3A4—Mitoxantrone—hematologic cancer	0.0141	0.0295	CbGbCtD
Alfuzosin—CYP3A4—Betamethasone—hematologic cancer	0.0126	0.0263	CbGbCtD
Alfuzosin—CYP3A4—Prednisolone—hematologic cancer	0.0124	0.026	CbGbCtD
Alfuzosin—CYP3A4—Prednisone—hematologic cancer	0.0117	0.0245	CbGbCtD
Alfuzosin—CYP3A4—Irinotecan—hematologic cancer	0.0111	0.0233	CbGbCtD
Alfuzosin—CYP3A4—Vinblastine—hematologic cancer	0.00989	0.0207	CbGbCtD
Alfuzosin—CYP3A4—Vincristine—hematologic cancer	0.00973	0.0203	CbGbCtD
Alfuzosin—CYP3A4—Etoposide—hematologic cancer	0.00891	0.0186	CbGbCtD
Alfuzosin—CYP3A4—Dexamethasone—hematologic cancer	0.00733	0.0153	CbGbCtD
Alfuzosin—CYP3A4—Doxorubicin—hematologic cancer	0.00608	0.0127	CbGbCtD
Alfuzosin—Prazosin—SLC22A1—hematologic cancer	0.00174	0.366	CrCbGaD
Alfuzosin—Prazosin—ABCG2—hematologic cancer	0.00122	0.256	CrCbGaD
Alfuzosin—Terazosin—ABCB1—hematologic cancer	0.000739	0.155	CrCbGaD
Alfuzosin—Doxazosin—ABCB1—hematologic cancer	0.000549	0.116	CrCbGaD
Alfuzosin—Prazosin—ABCB1—hematologic cancer	0.000506	0.107	CrCbGaD
Alfuzosin—Hepatobiliary disease—Doxorubicin—hematologic cancer	8.05e-05	0.000194	CcSEcCtD
Alfuzosin—Hypotension—Betamethasone—hematologic cancer	8.05e-05	0.000194	CcSEcCtD
Alfuzosin—Hypotension—Dexamethasone—hematologic cancer	8.05e-05	0.000194	CcSEcCtD
Alfuzosin—Nausea—Carmustine—hematologic cancer	8.04e-05	0.000194	CcSEcCtD
Alfuzosin—Angiopathy—Methotrexate—hematologic cancer	8.01e-05	0.000193	CcSEcCtD
Alfuzosin—Vomiting—Mitoxantrone—hematologic cancer	8e-05	0.000193	CcSEcCtD
Alfuzosin—Vomiting—Irinotecan—hematologic cancer	8e-05	0.000193	CcSEcCtD
Alfuzosin—Sinusitis—Doxorubicin—hematologic cancer	7.98e-05	0.000193	CcSEcCtD
Alfuzosin—Nausea—Alitretinoin—hematologic cancer	7.96e-05	0.000192	CcSEcCtD
Alfuzosin—Mediastinal disorder—Methotrexate—hematologic cancer	7.95e-05	0.000192	CcSEcCtD
Alfuzosin—Rash—Mitoxantrone—hematologic cancer	7.93e-05	0.000192	CcSEcCtD
Alfuzosin—Rash—Irinotecan—hematologic cancer	7.93e-05	0.000192	CcSEcCtD
Alfuzosin—Dermatitis—Mitoxantrone—hematologic cancer	7.93e-05	0.000191	CcSEcCtD
Alfuzosin—Dermatitis—Irinotecan—hematologic cancer	7.93e-05	0.000191	CcSEcCtD
Alfuzosin—Headache—Mitoxantrone—hematologic cancer	7.88e-05	0.00019	CcSEcCtD
Alfuzosin—Headache—Irinotecan—hematologic cancer	7.88e-05	0.00019	CcSEcCtD
Alfuzosin—Nausea—Ifosfamide—hematologic cancer	7.87e-05	0.00019	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	7.85e-05	0.000189	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Betamethasone—hematologic cancer	7.85e-05	0.000189	CcSEcCtD
Alfuzosin—Arthralgia—Prednisone—hematologic cancer	7.82e-05	0.000189	CcSEcCtD
Alfuzosin—Feeling abnormal—Triamcinolone—hematologic cancer	7.82e-05	0.000189	CcSEcCtD
Alfuzosin—Diarrhoea—Cisplatin—hematologic cancer	7.82e-05	0.000189	CcSEcCtD
Alfuzosin—Vomiting—Gemcitabine—hematologic cancer	7.79e-05	0.000188	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	7.77e-05	0.000188	CcSEcCtD
Alfuzosin—Discomfort—Prednisone—hematologic cancer	7.73e-05	0.000187	CcSEcCtD
Alfuzosin—Mental disorder—Methotrexate—hematologic cancer	7.73e-05	0.000187	CcSEcCtD
Alfuzosin—Rash—Gemcitabine—hematologic cancer	7.73e-05	0.000187	CcSEcCtD
Alfuzosin—Dermatitis—Gemcitabine—hematologic cancer	7.72e-05	0.000186	CcSEcCtD
Alfuzosin—Eye disorder—Epirubicin—hematologic cancer	7.72e-05	0.000186	CcSEcCtD
Alfuzosin—Headache—Gemcitabine—hematologic cancer	7.68e-05	0.000185	CcSEcCtD
Alfuzosin—Nausea—Vincristine—hematologic cancer	7.67e-05	0.000185	CcSEcCtD
Alfuzosin—Flushing—Epirubicin—hematologic cancer	7.66e-05	0.000185	CcSEcCtD
Alfuzosin—Cardiac disorder—Epirubicin—hematologic cancer	7.66e-05	0.000185	CcSEcCtD
Alfuzosin—Rhinitis—Doxorubicin—hematologic cancer	7.66e-05	0.000185	CcSEcCtD
Alfuzosin—Pharyngitis—Doxorubicin—hematologic cancer	7.58e-05	0.000183	CcSEcCtD
Alfuzosin—Dyspepsia—Dexamethasone—hematologic cancer	7.58e-05	0.000183	CcSEcCtD
Alfuzosin—Dyspepsia—Betamethasone—hematologic cancer	7.58e-05	0.000183	CcSEcCtD
Alfuzosin—Urinary tract disorder—Doxorubicin—hematologic cancer	7.55e-05	0.000182	CcSEcCtD
Alfuzosin—Urticaria—Triamcinolone—hematologic cancer	7.54e-05	0.000182	CcSEcCtD
Alfuzosin—Asthenia—Etoposide—hematologic cancer	7.51e-05	0.000181	CcSEcCtD
Alfuzosin—Connective tissue disorder—Doxorubicin—hematologic cancer	7.51e-05	0.000181	CcSEcCtD
Alfuzosin—Oedema—Prednisone—hematologic cancer	7.5e-05	0.000181	CcSEcCtD
Alfuzosin—Angiopathy—Epirubicin—hematologic cancer	7.49e-05	0.000181	CcSEcCtD
Alfuzosin—Urethral disorder—Doxorubicin—hematologic cancer	7.49e-05	0.000181	CcSEcCtD
Alfuzosin—Nausea—Mitoxantrone—hematologic cancer	7.47e-05	0.00018	CcSEcCtD
Alfuzosin—Nausea—Irinotecan—hematologic cancer	7.47e-05	0.00018	CcSEcCtD
Alfuzosin—Infection—Prednisone—hematologic cancer	7.45e-05	0.00018	CcSEcCtD
Alfuzosin—Mediastinal disorder—Epirubicin—hematologic cancer	7.44e-05	0.00018	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Dexamethasone—hematologic cancer	7.44e-05	0.00018	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Betamethasone—hematologic cancer	7.44e-05	0.00018	CcSEcCtD
Alfuzosin—Back pain—Methotrexate—hematologic cancer	7.43e-05	0.000179	CcSEcCtD
Alfuzosin—Fatigue—Betamethasone—hematologic cancer	7.43e-05	0.000179	CcSEcCtD
Alfuzosin—Fatigue—Dexamethasone—hematologic cancer	7.43e-05	0.000179	CcSEcCtD
Alfuzosin—Pruritus—Etoposide—hematologic cancer	7.4e-05	0.000179	CcSEcCtD
Alfuzosin—Shock—Prednisone—hematologic cancer	7.38e-05	0.000178	CcSEcCtD
Alfuzosin—Pain—Betamethasone—hematologic cancer	7.37e-05	0.000178	CcSEcCtD
Alfuzosin—Pain—Dexamethasone—hematologic cancer	7.37e-05	0.000178	CcSEcCtD
Alfuzosin—Nervous system disorder—Prednisone—hematologic cancer	7.36e-05	0.000178	CcSEcCtD
Alfuzosin—Tachycardia—Prednisone—hematologic cancer	7.32e-05	0.000177	CcSEcCtD
Alfuzosin—Skin disorder—Prednisone—hematologic cancer	7.29e-05	0.000176	CcSEcCtD
Alfuzosin—Nausea—Gemcitabine—hematologic cancer	7.28e-05	0.000176	CcSEcCtD
Alfuzosin—Vomiting—Cisplatin—hematologic cancer	7.26e-05	0.000175	CcSEcCtD
Alfuzosin—Hyperhidrosis—Prednisone—hematologic cancer	7.25e-05	0.000175	CcSEcCtD
Alfuzosin—Mental disorder—Epirubicin—hematologic cancer	7.23e-05	0.000175	CcSEcCtD
Alfuzosin—Rash—Cisplatin—hematologic cancer	7.2e-05	0.000174	CcSEcCtD
Alfuzosin—Dermatitis—Cisplatin—hematologic cancer	7.2e-05	0.000174	CcSEcCtD
Alfuzosin—Diarrhoea—Etoposide—hematologic cancer	7.16e-05	0.000173	CcSEcCtD
Alfuzosin—Eye disorder—Doxorubicin—hematologic cancer	7.14e-05	0.000172	CcSEcCtD
Alfuzosin—Ill-defined disorder—Methotrexate—hematologic cancer	7.13e-05	0.000172	CcSEcCtD
Alfuzosin—Feeling abnormal—Betamethasone—hematologic cancer	7.1e-05	0.000171	CcSEcCtD
Alfuzosin—Feeling abnormal—Dexamethasone—hematologic cancer	7.1e-05	0.000171	CcSEcCtD
Alfuzosin—Flushing—Doxorubicin—hematologic cancer	7.09e-05	0.000171	CcSEcCtD
Alfuzosin—Cardiac disorder—Doxorubicin—hematologic cancer	7.09e-05	0.000171	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Dexamethasone—hematologic cancer	7.04e-05	0.00017	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Betamethasone—hematologic cancer	7.04e-05	0.00017	CcSEcCtD
Alfuzosin—Back pain—Epirubicin—hematologic cancer	6.95e-05	0.000168	CcSEcCtD
Alfuzosin—Angiopathy—Doxorubicin—hematologic cancer	6.93e-05	0.000167	CcSEcCtD
Alfuzosin—Malaise—Methotrexate—hematologic cancer	6.93e-05	0.000167	CcSEcCtD
Alfuzosin—Dizziness—Etoposide—hematologic cancer	6.92e-05	0.000167	CcSEcCtD
Alfuzosin—Vertigo—Methotrexate—hematologic cancer	6.9e-05	0.000167	CcSEcCtD
Alfuzosin—Mediastinal disorder—Doxorubicin—hematologic cancer	6.89e-05	0.000166	CcSEcCtD
Alfuzosin—Urticaria—Betamethasone—hematologic cancer	6.84e-05	0.000165	CcSEcCtD
Alfuzosin—Urticaria—Dexamethasone—hematologic cancer	6.84e-05	0.000165	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Prednisone—hematologic cancer	6.83e-05	0.000165	CcSEcCtD
Alfuzosin—Dizziness—Prednisolone—hematologic cancer	6.83e-05	0.000165	CcSEcCtD
Alfuzosin—Asthenia—Triamcinolone—hematologic cancer	6.81e-05	0.000164	CcSEcCtD
Alfuzosin—Abdominal pain—Dexamethasone—hematologic cancer	6.81e-05	0.000164	CcSEcCtD
Alfuzosin—Abdominal pain—Betamethasone—hematologic cancer	6.81e-05	0.000164	CcSEcCtD
Alfuzosin—Nausea—Cisplatin—hematologic cancer	6.79e-05	0.000164	CcSEcCtD
Alfuzosin—Pruritus—Triamcinolone—hematologic cancer	6.72e-05	0.000162	CcSEcCtD
Alfuzosin—Mental disorder—Doxorubicin—hematologic cancer	6.69e-05	0.000162	CcSEcCtD
Alfuzosin—Ill-defined disorder—Epirubicin—hematologic cancer	6.67e-05	0.000161	CcSEcCtD
Alfuzosin—Vomiting—Etoposide—hematologic cancer	6.65e-05	0.000161	CcSEcCtD
Alfuzosin—Dyspepsia—Prednisone—hematologic cancer	6.6e-05	0.000159	CcSEcCtD
Alfuzosin—Rash—Etoposide—hematologic cancer	6.6e-05	0.000159	CcSEcCtD
Alfuzosin—Dermatitis—Etoposide—hematologic cancer	6.59e-05	0.000159	CcSEcCtD
Alfuzosin—Headache—Etoposide—hematologic cancer	6.56e-05	0.000158	CcSEcCtD
Alfuzosin—Chest pain—Methotrexate—hematologic cancer	6.54e-05	0.000158	CcSEcCtD
Alfuzosin—Arthralgia—Methotrexate—hematologic cancer	6.54e-05	0.000158	CcSEcCtD
Alfuzosin—Rash—Prednisolone—hematologic cancer	6.51e-05	0.000157	CcSEcCtD
Alfuzosin—Dermatitis—Prednisolone—hematologic cancer	6.5e-05	0.000157	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	6.49e-05	0.000157	CcSEcCtD
Alfuzosin—Malaise—Epirubicin—hematologic cancer	6.48e-05	0.000157	CcSEcCtD
Alfuzosin—Fatigue—Prednisone—hematologic cancer	6.47e-05	0.000156	CcSEcCtD
Alfuzosin—Headache—Prednisolone—hematologic cancer	6.47e-05	0.000156	CcSEcCtD
Alfuzosin—Discomfort—Methotrexate—hematologic cancer	6.46e-05	0.000156	CcSEcCtD
Alfuzosin—Vertigo—Epirubicin—hematologic cancer	6.46e-05	0.000156	CcSEcCtD
Alfuzosin—Syncope—Epirubicin—hematologic cancer	6.45e-05	0.000156	CcSEcCtD
Alfuzosin—Back pain—Doxorubicin—hematologic cancer	6.43e-05	0.000155	CcSEcCtD
Alfuzosin—Constipation—Prednisone—hematologic cancer	6.41e-05	0.000155	CcSEcCtD
Alfuzosin—Palpitations—Epirubicin—hematologic cancer	6.35e-05	0.000153	CcSEcCtD
Alfuzosin—Loss of consciousness—Epirubicin—hematologic cancer	6.32e-05	0.000153	CcSEcCtD
Alfuzosin—Dizziness—Triamcinolone—hematologic cancer	6.28e-05	0.000152	CcSEcCtD
Alfuzosin—Infection—Methotrexate—hematologic cancer	6.23e-05	0.00015	CcSEcCtD
Alfuzosin—Nausea—Etoposide—hematologic cancer	6.22e-05	0.00015	CcSEcCtD
Alfuzosin—Feeling abnormal—Prednisone—hematologic cancer	6.18e-05	0.000149	CcSEcCtD
Alfuzosin—Asthenia—Betamethasone—hematologic cancer	6.18e-05	0.000149	CcSEcCtD
Alfuzosin—Asthenia—Dexamethasone—hematologic cancer	6.18e-05	0.000149	CcSEcCtD
Alfuzosin—Ill-defined disorder—Doxorubicin—hematologic cancer	6.17e-05	0.000149	CcSEcCtD
Alfuzosin—Nervous system disorder—Methotrexate—hematologic cancer	6.15e-05	0.000148	CcSEcCtD
Alfuzosin—Thrombocytopenia—Methotrexate—hematologic cancer	6.14e-05	0.000148	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Prednisone—hematologic cancer	6.13e-05	0.000148	CcSEcCtD
Alfuzosin—Nausea—Prednisolone—hematologic cancer	6.13e-05	0.000148	CcSEcCtD
Alfuzosin—Arthralgia—Epirubicin—hematologic cancer	6.12e-05	0.000148	CcSEcCtD
Alfuzosin—Chest pain—Epirubicin—hematologic cancer	6.12e-05	0.000148	CcSEcCtD
Alfuzosin—Pruritus—Betamethasone—hematologic cancer	6.09e-05	0.000147	CcSEcCtD
Alfuzosin—Pruritus—Dexamethasone—hematologic cancer	6.09e-05	0.000147	CcSEcCtD
Alfuzosin—Skin disorder—Methotrexate—hematologic cancer	6.09e-05	0.000147	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	6.08e-05	0.000147	CcSEcCtD
Alfuzosin—Hyperhidrosis—Methotrexate—hematologic cancer	6.06e-05	0.000146	CcSEcCtD
Alfuzosin—Discomfort—Epirubicin—hematologic cancer	6.05e-05	0.000146	CcSEcCtD
Alfuzosin—Vomiting—Triamcinolone—hematologic cancer	6.04e-05	0.000146	CcSEcCtD
Alfuzosin—Malaise—Doxorubicin—hematologic cancer	6e-05	0.000145	CcSEcCtD
Alfuzosin—Rash—Triamcinolone—hematologic cancer	5.99e-05	0.000145	CcSEcCtD
Alfuzosin—Dry mouth—Epirubicin—hematologic cancer	5.98e-05	0.000145	CcSEcCtD
Alfuzosin—Dermatitis—Triamcinolone—hematologic cancer	5.98e-05	0.000144	CcSEcCtD
Alfuzosin—Vertigo—Doxorubicin—hematologic cancer	5.98e-05	0.000144	CcSEcCtD
Alfuzosin—Syncope—Doxorubicin—hematologic cancer	5.96e-05	0.000144	CcSEcCtD
Alfuzosin—Urticaria—Prednisone—hematologic cancer	5.96e-05	0.000144	CcSEcCtD
Alfuzosin—Headache—Triamcinolone—hematologic cancer	5.95e-05	0.000144	CcSEcCtD
Alfuzosin—Abdominal pain—Prednisone—hematologic cancer	5.93e-05	0.000143	CcSEcCtD
Alfuzosin—Diarrhoea—Betamethasone—hematologic cancer	5.89e-05	0.000142	CcSEcCtD
Alfuzosin—Diarrhoea—Dexamethasone—hematologic cancer	5.89e-05	0.000142	CcSEcCtD
Alfuzosin—Palpitations—Doxorubicin—hematologic cancer	5.88e-05	0.000142	CcSEcCtD
Alfuzosin—Oedema—Epirubicin—hematologic cancer	5.87e-05	0.000142	CcSEcCtD
Alfuzosin—Hypotension—Methotrexate—hematologic cancer	5.86e-05	0.000141	CcSEcCtD
Alfuzosin—Loss of consciousness—Doxorubicin—hematologic cancer	5.85e-05	0.000141	CcSEcCtD
Alfuzosin—Infection—Epirubicin—hematologic cancer	5.83e-05	0.000141	CcSEcCtD
Alfuzosin—Shock—Epirubicin—hematologic cancer	5.77e-05	0.000139	CcSEcCtD
Alfuzosin—Nervous system disorder—Epirubicin—hematologic cancer	5.75e-05	0.000139	CcSEcCtD
Alfuzosin—Thrombocytopenia—Epirubicin—hematologic cancer	5.74e-05	0.000139	CcSEcCtD
Alfuzosin—Tachycardia—Epirubicin—hematologic cancer	5.73e-05	0.000138	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Methotrexate—hematologic cancer	5.71e-05	0.000138	CcSEcCtD
Alfuzosin—Skin disorder—Epirubicin—hematologic cancer	5.7e-05	0.000138	CcSEcCtD
Alfuzosin—Dizziness—Dexamethasone—hematologic cancer	5.7e-05	0.000138	CcSEcCtD
Alfuzosin—Dizziness—Betamethasone—hematologic cancer	5.7e-05	0.000138	CcSEcCtD
Alfuzosin—Hyperhidrosis—Epirubicin—hematologic cancer	5.67e-05	0.000137	CcSEcCtD
Alfuzosin—Arthralgia—Doxorubicin—hematologic cancer	5.66e-05	0.000137	CcSEcCtD
Alfuzosin—Chest pain—Doxorubicin—hematologic cancer	5.66e-05	0.000137	CcSEcCtD
Alfuzosin—Nausea—Triamcinolone—hematologic cancer	5.64e-05	0.000136	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	5.62e-05	0.000136	CcSEcCtD
Alfuzosin—Discomfort—Doxorubicin—hematologic cancer	5.59e-05	0.000135	CcSEcCtD
Alfuzosin—Somnolence—Methotrexate—hematologic cancer	5.57e-05	0.000135	CcSEcCtD
Alfuzosin—Dry mouth—Doxorubicin—hematologic cancer	5.54e-05	0.000134	CcSEcCtD
Alfuzosin—Dyspepsia—Methotrexate—hematologic cancer	5.52e-05	0.000133	CcSEcCtD
Alfuzosin—Hypotension—Epirubicin—hematologic cancer	5.48e-05	0.000132	CcSEcCtD
Alfuzosin—Vomiting—Betamethasone—hematologic cancer	5.48e-05	0.000132	CcSEcCtD
Alfuzosin—Vomiting—Dexamethasone—hematologic cancer	5.48e-05	0.000132	CcSEcCtD
Alfuzosin—Rash—Dexamethasone—hematologic cancer	5.43e-05	0.000131	CcSEcCtD
Alfuzosin—Rash—Betamethasone—hematologic cancer	5.43e-05	0.000131	CcSEcCtD
Alfuzosin—Oedema—Doxorubicin—hematologic cancer	5.43e-05	0.000131	CcSEcCtD
Alfuzosin—Dermatitis—Dexamethasone—hematologic cancer	5.43e-05	0.000131	CcSEcCtD
Alfuzosin—Dermatitis—Betamethasone—hematologic cancer	5.43e-05	0.000131	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Methotrexate—hematologic cancer	5.41e-05	0.000131	CcSEcCtD
Alfuzosin—Fatigue—Methotrexate—hematologic cancer	5.4e-05	0.000131	CcSEcCtD
Alfuzosin—Headache—Betamethasone—hematologic cancer	5.4e-05	0.00013	CcSEcCtD
Alfuzosin—Headache—Dexamethasone—hematologic cancer	5.4e-05	0.00013	CcSEcCtD
Alfuzosin—Infection—Doxorubicin—hematologic cancer	5.39e-05	0.00013	CcSEcCtD
Alfuzosin—Asthenia—Prednisone—hematologic cancer	5.38e-05	0.00013	CcSEcCtD
Alfuzosin—Pain—Methotrexate—hematologic cancer	5.36e-05	0.000129	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Epirubicin—hematologic cancer	5.34e-05	0.000129	CcSEcCtD
Alfuzosin—Shock—Doxorubicin—hematologic cancer	5.34e-05	0.000129	CcSEcCtD
Alfuzosin—Nervous system disorder—Doxorubicin—hematologic cancer	5.32e-05	0.000129	CcSEcCtD
Alfuzosin—Thrombocytopenia—Doxorubicin—hematologic cancer	5.31e-05	0.000128	CcSEcCtD
Alfuzosin—Pruritus—Prednisone—hematologic cancer	5.31e-05	0.000128	CcSEcCtD
Alfuzosin—Tachycardia—Doxorubicin—hematologic cancer	5.3e-05	0.000128	CcSEcCtD
Alfuzosin—Skin disorder—Doxorubicin—hematologic cancer	5.27e-05	0.000127	CcSEcCtD
Alfuzosin—Hyperhidrosis—Doxorubicin—hematologic cancer	5.25e-05	0.000127	CcSEcCtD
Alfuzosin—Somnolence—Epirubicin—hematologic cancer	5.22e-05	0.000126	CcSEcCtD
Alfuzosin—Feeling abnormal—Methotrexate—hematologic cancer	5.17e-05	0.000125	CcSEcCtD
Alfuzosin—Dyspepsia—Epirubicin—hematologic cancer	5.16e-05	0.000125	CcSEcCtD
Alfuzosin—Diarrhoea—Prednisone—hematologic cancer	5.13e-05	0.000124	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Methotrexate—hematologic cancer	5.13e-05	0.000124	CcSEcCtD
Alfuzosin—Nausea—Dexamethasone—hematologic cancer	5.12e-05	0.000124	CcSEcCtD
Alfuzosin—Nausea—Betamethasone—hematologic cancer	5.12e-05	0.000124	CcSEcCtD
Alfuzosin—Hypotension—Doxorubicin—hematologic cancer	5.07e-05	0.000122	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Epirubicin—hematologic cancer	5.06e-05	0.000122	CcSEcCtD
Alfuzosin—Fatigue—Epirubicin—hematologic cancer	5.06e-05	0.000122	CcSEcCtD
Alfuzosin—Constipation—Epirubicin—hematologic cancer	5.02e-05	0.000121	CcSEcCtD
Alfuzosin—Pain—Epirubicin—hematologic cancer	5.02e-05	0.000121	CcSEcCtD
Alfuzosin—Urticaria—Methotrexate—hematologic cancer	4.98e-05	0.00012	CcSEcCtD
Alfuzosin—Dizziness—Prednisone—hematologic cancer	4.96e-05	0.00012	CcSEcCtD
Alfuzosin—Abdominal pain—Methotrexate—hematologic cancer	4.96e-05	0.00012	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.95e-05	0.000119	CcSEcCtD
Alfuzosin—Feeling abnormal—Epirubicin—hematologic cancer	4.83e-05	0.000117	CcSEcCtD
Alfuzosin—Somnolence—Doxorubicin—hematologic cancer	4.83e-05	0.000117	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Epirubicin—hematologic cancer	4.8e-05	0.000116	CcSEcCtD
Alfuzosin—Dyspepsia—Doxorubicin—hematologic cancer	4.78e-05	0.000115	CcSEcCtD
Alfuzosin—Vomiting—Prednisone—hematologic cancer	4.77e-05	0.000115	CcSEcCtD
Alfuzosin—Rash—Prednisone—hematologic cancer	4.73e-05	0.000114	CcSEcCtD
Alfuzosin—Dermatitis—Prednisone—hematologic cancer	4.72e-05	0.000114	CcSEcCtD
Alfuzosin—Headache—Prednisone—hematologic cancer	4.7e-05	0.000113	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Doxorubicin—hematologic cancer	4.69e-05	0.000113	CcSEcCtD
Alfuzosin—Fatigue—Doxorubicin—hematologic cancer	4.68e-05	0.000113	CcSEcCtD
Alfuzosin—Urticaria—Epirubicin—hematologic cancer	4.66e-05	0.000113	CcSEcCtD
Alfuzosin—Pain—Doxorubicin—hematologic cancer	4.64e-05	0.000112	CcSEcCtD
Alfuzosin—Constipation—Doxorubicin—hematologic cancer	4.64e-05	0.000112	CcSEcCtD
Alfuzosin—Abdominal pain—Epirubicin—hematologic cancer	4.64e-05	0.000112	CcSEcCtD
Alfuzosin—Asthenia—Methotrexate—hematologic cancer	4.5e-05	0.000109	CcSEcCtD
Alfuzosin—Feeling abnormal—Doxorubicin—hematologic cancer	4.47e-05	0.000108	CcSEcCtD
Alfuzosin—Nausea—Prednisone—hematologic cancer	4.46e-05	0.000108	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.44e-05	0.000107	CcSEcCtD
Alfuzosin—Pruritus—Methotrexate—hematologic cancer	4.43e-05	0.000107	CcSEcCtD
Alfuzosin—Urticaria—Doxorubicin—hematologic cancer	4.31e-05	0.000104	CcSEcCtD
Alfuzosin—Abdominal pain—Doxorubicin—hematologic cancer	4.29e-05	0.000104	CcSEcCtD
Alfuzosin—Diarrhoea—Methotrexate—hematologic cancer	4.29e-05	0.000104	CcSEcCtD
Alfuzosin—Asthenia—Epirubicin—hematologic cancer	4.21e-05	0.000102	CcSEcCtD
Alfuzosin—Pruritus—Epirubicin—hematologic cancer	4.15e-05	0.0001	CcSEcCtD
Alfuzosin—Dizziness—Methotrexate—hematologic cancer	4.15e-05	0.0001	CcSEcCtD
Alfuzosin—Diarrhoea—Epirubicin—hematologic cancer	4.01e-05	9.69e-05	CcSEcCtD
Alfuzosin—Vomiting—Methotrexate—hematologic cancer	3.99e-05	9.62e-05	CcSEcCtD
Alfuzosin—Rash—Methotrexate—hematologic cancer	3.95e-05	9.54e-05	CcSEcCtD
Alfuzosin—Dermatitis—Methotrexate—hematologic cancer	3.95e-05	9.54e-05	CcSEcCtD
Alfuzosin—Headache—Methotrexate—hematologic cancer	3.93e-05	9.48e-05	CcSEcCtD
Alfuzosin—Asthenia—Doxorubicin—hematologic cancer	3.89e-05	9.4e-05	CcSEcCtD
Alfuzosin—Dizziness—Epirubicin—hematologic cancer	3.88e-05	9.37e-05	CcSEcCtD
Alfuzosin—Pruritus—Doxorubicin—hematologic cancer	3.84e-05	9.27e-05	CcSEcCtD
Alfuzosin—Vomiting—Epirubicin—hematologic cancer	3.73e-05	9.01e-05	CcSEcCtD
Alfuzosin—Nausea—Methotrexate—hematologic cancer	3.72e-05	8.99e-05	CcSEcCtD
Alfuzosin—Diarrhoea—Doxorubicin—hematologic cancer	3.71e-05	8.97e-05	CcSEcCtD
Alfuzosin—Rash—Epirubicin—hematologic cancer	3.7e-05	8.93e-05	CcSEcCtD
Alfuzosin—Dermatitis—Epirubicin—hematologic cancer	3.7e-05	8.92e-05	CcSEcCtD
Alfuzosin—Headache—Epirubicin—hematologic cancer	3.68e-05	8.87e-05	CcSEcCtD
Alfuzosin—Dizziness—Doxorubicin—hematologic cancer	3.59e-05	8.67e-05	CcSEcCtD
Alfuzosin—Nausea—Epirubicin—hematologic cancer	3.48e-05	8.41e-05	CcSEcCtD
Alfuzosin—Vomiting—Doxorubicin—hematologic cancer	3.45e-05	8.33e-05	CcSEcCtD
Alfuzosin—Rash—Doxorubicin—hematologic cancer	3.42e-05	8.26e-05	CcSEcCtD
Alfuzosin—Dermatitis—Doxorubicin—hematologic cancer	3.42e-05	8.26e-05	CcSEcCtD
Alfuzosin—Headache—Doxorubicin—hematologic cancer	3.4e-05	8.21e-05	CcSEcCtD
Alfuzosin—Nausea—Doxorubicin—hematologic cancer	3.22e-05	7.79e-05	CcSEcCtD
Alfuzosin—CYP3A4—Metabolism—HMMR—hematologic cancer	1.31e-05	0.000128	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—NCOR1—hematologic cancer	1.31e-05	0.000127	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—JAK2—hematologic cancer	1.3e-05	0.000126	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CSF2—hematologic cancer	1.29e-05	0.000126	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—FGF1—hematologic cancer	1.29e-05	0.000126	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—MAP2K1—hematologic cancer	1.29e-05	0.000126	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—GRB2—hematologic cancer	1.28e-05	0.000125	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PIK3CD—hematologic cancer	1.28e-05	0.000125	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PDGFA—hematologic cancer	1.28e-05	0.000125	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—FOXO1—hematologic cancer	1.27e-05	0.000124	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—FGFR3—hematologic cancer	1.27e-05	0.000124	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—IL2—hematologic cancer	1.27e-05	0.000124	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PDGFRB—hematologic cancer	1.27e-05	0.000124	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—KITLG—hematologic cancer	1.26e-05	0.000123	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MAPK14—hematologic cancer	1.26e-05	0.000123	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—PIK3CB—hematologic cancer	1.26e-05	0.000123	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PDGFRA—hematologic cancer	1.25e-05	0.000122	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—JAK1—hematologic cancer	1.25e-05	0.000122	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PRKCG—hematologic cancer	1.25e-05	0.000122	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—ESR1—hematologic cancer	1.24e-05	0.000121	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—STAT5A—hematologic cancer	1.23e-05	0.00012	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—PIK3CB—hematologic cancer	1.23e-05	0.00012	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ARNTL—hematologic cancer	1.23e-05	0.00012	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CDKN2B—hematologic cancer	1.22e-05	0.000119	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—FN1—hematologic cancer	1.22e-05	0.000119	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PIK3R1—hematologic cancer	1.21e-05	0.000118	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—BAD—hematologic cancer	1.21e-05	0.000118	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—NFKBIA—hematologic cancer	1.21e-05	0.000118	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ACP5—hematologic cancer	1.2e-05	0.000117	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CA9—hematologic cancer	1.2e-05	0.000117	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—NOTCH1—hematologic cancer	1.2e-05	0.000117	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CD86—hematologic cancer	1.18e-05	0.000115	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NCOR2—hematologic cancer	1.18e-05	0.000115	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—JAK2—hematologic cancer	1.18e-05	0.000115	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CD80—hematologic cancer	1.17e-05	0.000114	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3CG—hematologic cancer	1.17e-05	0.000114	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—KIT—hematologic cancer	1.17e-05	0.000114	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—NRAS—hematologic cancer	1.17e-05	0.000114	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—HES1—hematologic cancer	1.17e-05	0.000114	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IL2RA—hematologic cancer	1.16e-05	0.000114	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—NCOR1—hematologic cancer	1.16e-05	0.000113	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—IL2—hematologic cancer	1.16e-05	0.000113	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TERT—hematologic cancer	1.15e-05	0.000112	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PTPN11—hematologic cancer	1.15e-05	0.000112	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—FGF1—hematologic cancer	1.15e-05	0.000112	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CSF2—hematologic cancer	1.15e-05	0.000112	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—FOXO1—hematologic cancer	1.13e-05	0.00011	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—IL2—hematologic cancer	1.13e-05	0.00011	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PDGFRB—hematologic cancer	1.13e-05	0.00011	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—IDH1—hematologic cancer	1.13e-05	0.00011	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PDGFB—hematologic cancer	1.12e-05	0.00011	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—MAPK3—hematologic cancer	1.12e-05	0.000109	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PIK3CB—hematologic cancer	1.12e-05	0.000109	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CREB1—hematologic cancer	1.11e-05	0.000108	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTO1—hematologic cancer	1.11e-05	0.000108	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ABCC3—hematologic cancer	1.11e-05	0.000108	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—TXN—hematologic cancer	1.11e-05	0.000108	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PDGFRA—hematologic cancer	1.11e-05	0.000108	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PRKCG—hematologic cancer	1.11e-05	0.000108	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—JAK1—hematologic cancer	1.11e-05	0.000108	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—BRAF—hematologic cancer	1.1e-05	0.000107	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TSC2—hematologic cancer	1.1e-05	0.000107	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CCL2—hematologic cancer	1.09e-05	0.000106	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SPHK1—hematologic cancer	1.09e-05	0.000106	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IL6R—hematologic cancer	1.09e-05	0.000106	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CREBBP—hematologic cancer	1.08e-05	0.000106	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—FGFR3—hematologic cancer	1.06e-05	0.000103	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MAPK14—hematologic cancer	1.05e-05	0.000102	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—UGT1A1—hematologic cancer	1.05e-05	0.000102	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MAP2K1—hematologic cancer	1.03e-05	0.000101	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IL2RA—hematologic cancer	1.03e-05	0.000101	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3CD—hematologic cancer	1.03e-05	0.0001	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—IL2—hematologic cancer	1.03e-05	0.0001	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ESR1—hematologic cancer	1.03e-05	0.0001	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TERT—hematologic cancer	1.02e-05	9.97e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—PIK3CA—hematologic cancer	1.02e-05	9.92e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CRABP1—hematologic cancer	1.02e-05	9.92e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SLC22A1—hematologic cancer	1.02e-05	9.92e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—FN1—hematologic cancer	1.01e-05	9.88e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—KRAS—hematologic cancer	1.01e-05	9.81e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—BAD—hematologic cancer	1e-05	9.77e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—NFKBIA—hematologic cancer	1e-05	9.77e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PDGFB—hematologic cancer	9.98e-06	9.73e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—NOTCH1—hematologic cancer	9.92e-06	9.67e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ALOX5—hematologic cancer	9.92e-06	9.67e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—FGF2—hematologic cancer	9.84e-06	9.59e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TSC2—hematologic cancer	9.76e-06	9.51e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CD80—hematologic cancer	9.72e-06	9.48e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3R1—hematologic cancer	9.7e-06	9.46e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3CG—hematologic cancer	9.7e-06	9.46e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—KIT—hematologic cancer	9.7e-06	9.46e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—NRAS—hematologic cancer	9.7e-06	9.46e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NUP98—hematologic cancer	9.6e-06	9.36e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PTPN11—hematologic cancer	9.53e-06	9.29e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—JAK2—hematologic cancer	9.43e-06	9.19e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—FGFR3—hematologic cancer	9.39e-06	9.15e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ADCY7—hematologic cancer	9.32e-06	9.09e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NCOA3—hematologic cancer	9.32e-06	9.09e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MAPK14—hematologic cancer	9.29e-06	9.06e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—MAPK3—hematologic cancer	9.29e-06	9.06e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NUP214—hematologic cancer	9.26e-06	9.02e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—PIK3CA—hematologic cancer	9.24e-06	9.01e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CREB1—hematologic cancer	9.24e-06	9e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MDM2—hematologic cancer	9.21e-06	8.97e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—BRAF—hematologic cancer	9.12e-06	8.89e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ESR1—hematologic cancer	9.12e-06	8.89e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ABCG2—hematologic cancer	9.07e-06	8.84e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—MTR—hematologic cancer	9.07e-06	8.84e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CCL2—hematologic cancer	9.04e-06	8.81e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IL6R—hematologic cancer	9.01e-06	8.78e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—FN1—hematologic cancer	9.01e-06	8.78e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CREBBP—hematologic cancer	9e-06	8.77e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MTOR—hematologic cancer	8.96e-06	8.73e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3CB—hematologic cancer	8.96e-06	8.73e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—BAD—hematologic cancer	8.9e-06	8.67e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—NFKBIA—hematologic cancer	8.9e-06	8.67e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ENO2—hematologic cancer	8.89e-06	8.67e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—NOTCH1—hematologic cancer	8.81e-06	8.59e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CD80—hematologic cancer	8.63e-06	8.42e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTT1—hematologic cancer	8.63e-06	8.41e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3CG—hematologic cancer	8.62e-06	8.4e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—KIT—hematologic cancer	8.62e-06	8.4e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—NRAS—hematologic cancer	8.62e-06	8.4e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MAP2K1—hematologic cancer	8.59e-06	8.37e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—HRAS—hematologic cancer	8.55e-06	8.34e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3CD—hematologic cancer	8.53e-06	8.31e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PTPN11—hematologic cancer	8.47e-06	8.25e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—PIK3CA—hematologic cancer	8.45e-06	8.24e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SDC1—hematologic cancer	8.43e-06	8.22e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CDKN1B—hematologic cancer	8.41e-06	8.19e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—KRAS—hematologic cancer	8.35e-06	8.14e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—AKT1—hematologic cancer	8.32e-06	8.11e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—MAPK3—hematologic cancer	8.25e-06	8.05e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CASP3—hematologic cancer	8.24e-06	8.03e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IL2—hematologic cancer	8.23e-06	8.02e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CREB1—hematologic cancer	8.2e-06	8e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—IL6—hematologic cancer	8.18e-06	7.98e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—FGF2—hematologic cancer	8.17e-06	7.96e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—BRAF—hematologic cancer	8.1e-06	7.9e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3R1—hematologic cancer	8.05e-06	7.85e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CCL2—hematologic cancer	8.03e-06	7.82e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CCND1—hematologic cancer	8.02e-06	7.82e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IL6R—hematologic cancer	8e-06	7.8e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—JUN—hematologic cancer	8e-06	7.8e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CREBBP—hematologic cancer	7.99e-06	7.79e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—JAK2—hematologic cancer	7.83e-06	7.63e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CDKN1A—hematologic cancer	7.76e-06	7.56e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PTEN—hematologic cancer	7.74e-06	7.55e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—PIK3CA—hematologic cancer	7.67e-06	7.48e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MDM2—hematologic cancer	7.64e-06	7.45e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MAP2K1—hematologic cancer	7.63e-06	7.43e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3CD—hematologic cancer	7.58e-06	7.39e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MAPK8—hematologic cancer	7.57e-06	7.38e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—AKT1—hematologic cancer	7.55e-06	7.36e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—PIK3CA—hematologic cancer	7.5e-06	7.32e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3CB—hematologic cancer	7.43e-06	7.25e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MTOR—hematologic cancer	7.43e-06	7.25e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—KRAS—hematologic cancer	7.42e-06	7.23e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—EP300—hematologic cancer	7.38e-06	7.2e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—FGF2—hematologic cancer	7.25e-06	7.07e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—SRC—hematologic cancer	7.18e-06	7e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CD44—hematologic cancer	7.17e-06	6.99e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NQO1—hematologic cancer	7.17e-06	6.99e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3R1—hematologic cancer	7.15e-06	6.97e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—HRAS—hematologic cancer	7.1e-06	6.92e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—VEGFA—hematologic cancer	6.99e-06	6.82e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CDKN1B—hematologic cancer	6.98e-06	6.8e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—JAK2—hematologic cancer	6.95e-06	6.78e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—STAT3—hematologic cancer	6.92e-06	6.75e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—NRAS—hematologic cancer	6.91e-06	6.73e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—AKT1—hematologic cancer	6.9e-06	6.73e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CASP3—hematologic cancer	6.84e-06	6.67e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IL2—hematologic cancer	6.83e-06	6.66e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PIK3CA—hematologic cancer	6.81e-06	6.64e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—IL6—hematologic cancer	6.79e-06	6.62e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MDM2—hematologic cancer	6.79e-06	6.62e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYCS—hematologic cancer	6.78e-06	6.61e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	6.74e-06	6.57e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CCND1—hematologic cancer	6.66e-06	6.49e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—JUN—hematologic cancer	6.64e-06	6.47e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MAPK3—hematologic cancer	6.61e-06	6.45e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MTOR—hematologic cancer	6.6e-06	6.44e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3CB—hematologic cancer	6.6e-06	6.44e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CDKN1A—hematologic cancer	6.44e-06	6.28e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MYC—hematologic cancer	6.43e-06	6.27e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PTEN—hematologic cancer	6.42e-06	6.26e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—TGFB1—hematologic cancer	6.42e-06	6.26e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	6.3e-06	6.15e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MAPK8—hematologic cancer	6.28e-06	6.13e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—AKT1—hematologic cancer	6.27e-06	6.11e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	6.2e-06	6.04e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	6.13e-06	5.98e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—EP300—hematologic cancer	6.13e-06	5.97e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	6.07e-06	5.92e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IL2—hematologic cancer	6.06e-06	5.91e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	6.03e-06	5.88e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTP1—hematologic cancer	5.98e-06	5.83e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—SRC—hematologic cancer	5.96e-06	5.81e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—KRAS—hematologic cancer	5.94e-06	5.79e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	5.91e-06	5.76e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—JUN—hematologic cancer	5.9e-06	5.75e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	5.8e-06	5.66e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	5.75e-06	5.6e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	5.73e-06	5.59e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	5.72e-06	5.58e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	5.71e-06	5.56e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ABCB1—hematologic cancer	5.66e-06	5.52e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	5.58e-06	5.44e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	5.57e-06	5.43e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTM1—hematologic cancer	5.49e-06	5.36e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NCOR1—hematologic cancer	5.49e-06	5.36e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	5.49e-06	5.35e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3CA—hematologic cancer	5.46e-06	5.32e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—EP300—hematologic cancer	5.44e-06	5.3e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MYC—hematologic cancer	5.34e-06	5.2e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	5.33e-06	5.19e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—SRC—hematologic cancer	5.29e-06	5.16e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—TP53—hematologic cancer	5.28e-06	5.15e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	5.15e-06	5.02e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	5.1e-06	4.97e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	5.09e-06	4.96e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—HRAS—hematologic cancer	5.05e-06	4.92e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	4.93e-06	4.81e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	4.88e-06	4.75e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—MTHFR—hematologic cancer	4.86e-06	4.73e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IL6—hematologic cancer	4.84e-06	4.71e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MYC—hematologic cancer	4.74e-06	4.62e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	4.73e-06	4.61e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	4.53e-06	4.42e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—AKT1—hematologic cancer	4.46e-06	4.35e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TP53—hematologic cancer	4.38e-06	4.27e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	4.38e-06	4.27e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	4.19e-06	4.09e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3CG—hematologic cancer	4.08e-06	3.98e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	4.03e-06	3.92e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IL6—hematologic cancer	4.01e-06	3.91e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TP53—hematologic cancer	3.89e-06	3.8e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CREBBP—hematologic cancer	3.78e-06	3.69e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	3.72e-06	3.63e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	3.7e-06	3.61e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3CD—hematologic cancer	3.59e-06	3.5e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IL6—hematologic cancer	3.56e-06	3.47e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ALB—hematologic cancer	3.54e-06	3.45e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3R1—hematologic cancer	3.39e-06	3.3e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	3.29e-06	3.21e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3CB—hematologic cancer	3.13e-06	3.05e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PTEN—hematologic cancer	2.7e-06	2.63e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—EP300—hematologic cancer	2.58e-06	2.51e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.91e-06	1.86e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—AKT1—hematologic cancer	1.56e-06	1.52e-05	CbGpPWpGaD
